256 related articles for article (PubMed ID: 25213272)
1. Combination of hypothiocyanite and lactoferrin (ALX-109) enhances the ability of tobramycin and aztreonam to eliminate Pseudomonas aeruginosa biofilms growing on cystic fibrosis airway epithelial cells.
Moreau-Marquis S; Coutermarsh B; Stanton BA
J Antimicrob Chemother; 2015 Jan; 70(1):160-6. PubMed ID: 25213272
[TBL] [Abstract][Full Text] [Related]
2. In vitro evaluation of tobramycin and aztreonam versus Pseudomonas aeruginosa biofilms on cystic fibrosis-derived human airway epithelial cells.
Yu Q; Griffin EF; Moreau-Marquis S; Schwartzman JD; Stanton BA; O'Toole GA
J Antimicrob Chemother; 2012 Nov; 67(11):2673-81. PubMed ID: 22843834
[TBL] [Abstract][Full Text] [Related]
3. Activity of hypothiocyanite and lactoferrin (ALX-009) against respiratory cystic fibrosis pathogens in sputum.
Tunney MM; Payne JE; McGrath SJ; Einarsson GG; Ingram RJ; Gilpin DF; Juarez-Perez V; Elborn JS
J Antimicrob Chemother; 2018 Dec; 73(12):3391-3397. PubMed ID: 30219825
[TBL] [Abstract][Full Text] [Related]
4. Eradication of Pseudomonas aeruginosa biofilms on cultured airway cells by a fosfomycin/tobramycin antibiotic combination.
Anderson GG; Kenney TF; Macleod DL; Henig NR; O'Toole GA
Pathog Dis; 2013 Feb; 67(1):39-45. PubMed ID: 23620118
[TBL] [Abstract][Full Text] [Related]
5. In vitro analysis of tobramycin-treated Pseudomonas aeruginosa biofilms on cystic fibrosis-derived airway epithelial cells.
Anderson GG; Moreau-Marquis S; Stanton BA; O'Toole GA
Infect Immun; 2008 Apr; 76(4):1423-33. PubMed ID: 18212077
[TBL] [Abstract][Full Text] [Related]
6. The ionophore oxyclozanide enhances tobramycin killing of Pseudomonas aeruginosa biofilms by permeabilizing cells and depolarizing the membrane potential.
Maiden MM; Zachos MP; Waters CM
J Antimicrob Chemother; 2019 Apr; 74(4):894-906. PubMed ID: 30624737
[TBL] [Abstract][Full Text] [Related]
7. Synergistic effects of inhaled aztreonam plus tobramycin on hypermutable cystic fibrosis Pseudomonas aeruginosa isolates in a dynamic biofilm model evaluated by mechanism-based modelling and whole genome sequencing.
Breen SKJ; Harper M; López-Causapé C; Rogers KE; Tait JR; Smallman TR; Lang Y; Lee WL; Zhou J; Zhang Y; Bulitta JB; Nation RL; Oliver A; Boyce JD; Landersdorfer CB
Int J Antimicrob Agents; 2024 Jun; 63(6):107161. PubMed ID: 38561094
[TBL] [Abstract][Full Text] [Related]
8. Tobramycin and FDA-approved iron chelators eliminate Pseudomonas aeruginosa biofilms on cystic fibrosis cells.
Moreau-Marquis S; O'Toole GA; Stanton BA
Am J Respir Cell Mol Biol; 2009 Sep; 41(3):305-13. PubMed ID: 19168700
[TBL] [Abstract][Full Text] [Related]
9. Dispersal of Epithelium-Associated Pseudomonas aeruginosa Biofilms.
Zemke AC; D'Amico EJ; Snell EC; Torres AM; Kasturiarachi N; Bomberger JM
mSphere; 2020 Jul; 5(4):. PubMed ID: 32669459
[No Abstract] [Full Text] [Related]
10. Sequential Treatment of Biofilms with Aztreonam and Tobramycin Is a Novel Strategy for Combating Pseudomonas aeruginosa Chronic Respiratory Infections.
Rojo-Molinero E; Macià MD; Rubio R; Moyà B; Cabot G; López-Causapé C; Pérez JL; Cantón R; Oliver A
Antimicrob Agents Chemother; 2016 May; 60(5):2912-22. PubMed ID: 26926631
[TBL] [Abstract][Full Text] [Related]
11. The DeltaF508-CFTR mutation results in increased biofilm formation by Pseudomonas aeruginosa by increasing iron availability.
Moreau-Marquis S; Bomberger JM; Anderson GG; Swiatecka-Urban A; Ye S; O'Toole GA; Stanton BA
Am J Physiol Lung Cell Mol Physiol; 2008 Jul; 295(1):L25-37. PubMed ID: 18359885
[TBL] [Abstract][Full Text] [Related]
12. Effect of oxygen limitation on the in vitro antimicrobial susceptibility of clinical isolates of Pseudomonas aeruginosa grown planktonically and as biofilms.
Field TR; White A; Elborn JS; Tunney MM
Eur J Clin Microbiol Infect Dis; 2005 Oct; 24(10):677-87. PubMed ID: 16249934
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of long-term co-administration of tobramycin and clarithromycin in a mature biofilm model of cystic fibrosis clinical isolates of Pseudomonas aeruginosa.
Tré-Hardy M; Traore H; El Manssouri N; Vanderbist F; Vaneechoutte M; Devleeschouwer MJ
Int J Antimicrob Agents; 2009 Oct; 34(4):370-4. PubMed ID: 19505804
[TBL] [Abstract][Full Text] [Related]
14. Tobramycin-Treated Pseudomonas aeruginosa PA14 Enhances Streptococcus constellatus 7155 Biofilm Formation in a Cystic Fibrosis Model System.
Price KE; Naimie AA; Griffin EF; Bay C; O'Toole GA
J Bacteriol; 2016 Jan; 198(2):237-47. PubMed ID: 26483523
[TBL] [Abstract][Full Text] [Related]
15. In vitro approach to study the synergistic effects of tobramycin and clarithromycin against Pseudomonas aeruginosa biofilms using prokaryotic or eukaryotic culture media.
Thellin O; Zorzi W; Jolois O; Elmoualij B; Duysens G; Cahay B; Streel B; Charif M; Bastin R; Heinen E; Quatresooz P
Int J Antimicrob Agents; 2015 Jul; 46(1):33-8. PubMed ID: 25963337
[TBL] [Abstract][Full Text] [Related]
16. An Antipersister Strategy for Treatment of Chronic Pseudomonas aeruginosa Infections.
Koeva M; Gutu AD; Hebert W; Wager JD; Yonker LM; O'Toole GA; Ausubel FM; Moskowitz SM; Joseph-McCarthy D
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28923873
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of the combination of tobramycin and a macrolide in an in vitro Pseudomonas aeruginosa mature biofilm model.
Tré-Hardy M; Nagant C; El Manssouri N; Vanderbist F; Traore H; Vaneechoutte M; Dehaye JP
Antimicrob Agents Chemother; 2010 Oct; 54(10):4409-15. PubMed ID: 20696878
[TBL] [Abstract][Full Text] [Related]
18. Synergy of silver nanoparticles and aztreonam against Pseudomonas aeruginosa PAO1 biofilms.
Habash MB; Park AJ; Vis EC; Harris RJ; Khursigara CM
Antimicrob Agents Chemother; 2014 Oct; 58(10):5818-30. PubMed ID: 25049240
[TBL] [Abstract][Full Text] [Related]
19. Engineered cationic antimicrobial peptide (eCAP) prevents Pseudomonas aeruginosa biofilm growth on airway epithelial cells.
Lashua LP; Melvin JA; Deslouches B; Pilewski JM; Montelaro RC; Bomberger JM
J Antimicrob Chemother; 2016 Aug; 71(8):2200-7. PubMed ID: 27231279
[TBL] [Abstract][Full Text] [Related]
20. Investigation of the enhanced antimicrobial activity of combination dry powder inhaler formulations of lactoferrin.
Marshall LJ; Oguejiofor W; Price R; Shur J
Int J Pharm; 2016 Dec; 514(2):399-406. PubMed ID: 27628783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
